In the US and in Europe, combination therapy with a BRAF-inhibitor and a MEK-inhibitor is approved for patients with unresectable BRAF-V600-mutated melanoma as well as for adjuvant treatment in stage III melanoma [2, 5–7]. This evidence concerns the gene MAP2K7 and melanoma.